@article{uoadl:3128790,
    volume = "14",
    number = "5",
    pages = "741-744",
    journal = "Europace",
    issn = "1099-5129, 1532-2092",
    keywords = "anticoagulant agent;  antivitamin K;  dabigatran;  heparin;  rivaroxaban, anticoagulant therapy;  article;  bleeding;  cardiac resynchronization therapy;  cardiac resynchronization therapy device;  coronary artery disease;  defibrillator;  heart atrium fibrillation;  heart atrium pacemaker;  heart valve prosthesis;  hematoma;  human;  international normalized ratio;  priority journal;  risk factor;  stent;  stroke;  thromboembolism;  transesophageal echocardiography;  treatment response;  wound drainage, Anticoagulants;  Atrial Fibrillation;  Cardiac Pacing, Artificial;  Cardiac Resynchronization Therapy;  Catheter Ablation;  Defibrillators, Implantable;  Health Care Surveys;  Humans;  Professional Practice;  Risk Assessment;  Risk Factors",
    BIBTEX_ENTRY = "article",
    year = "2012",
    author = "Lip, G.Y.H. and Proclemer, A. and Dagres, N. and Bongiorni, M.G. and Lewalter, T. and Blomstrom-Lundqvist, C.",
    abstract = "This EP Wire surveyed clinical practice with regard to the use of antithrombotic therapy in relation to device implantation (pacemakers, ICT, resynchronization therapy) and atrial fibrillation ablation in 71 centres-members of the European Heart Rhythm Association research network. The results of this survey show variation in clinical practice, but reassuringly some consistency with guidelines and consensus recommendations on the management of periprocedure (devices, ablation) antithrombotic therapy. © 2011 The Author.",
    title = "Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation",
    doi = "10.1093/EUROPACE/EUS105"
}